X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs NOVARTIS - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES NOVARTIS DIVIS LABORATORIES/
NOVARTIS
 
P/E (TTM) x 18.0 342.6 5.3% View Chart
P/BV x 3.9 16.9 23.1% View Chart
Dividend Yield % 1.6 1.7 92.7%  

Financials

 DIVIS LABORATORIES   NOVARTIS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
NOVARTIS
Mar-16
DIVIS LABORATORIES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs2,484982 252.9%   
Low Rs918556 165.1%   
Sales per share (Unadj.) Rs142.3252.9 56.2%  
Earnings per share (Unadj.) Rs41.962.1 67.4%  
Cash flow per share (Unadj.) Rs46.363.3 73.2%  
Dividends per share (Unadj.) Rs10.0010.00 100.0%  
Dividend yield (eoy) %0.61.3 45.2%  
Book value per share (Unadj.) Rs161.5363.6 44.4%  
Shares outstanding (eoy) m265.4731.96 830.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x12.03.0 393.2%   
Avg P/E ratio x40.612.4 328.1%  
P/CF ratio (eoy) x36.712.2 302.1%  
Price / Book Value ratio x10.52.1 497.9%  
Dividend payout %23.916.1 148.4%   
Avg Mkt Cap Rs m451,52524,580 1,836.9%   
No. of employees `0003.70.8 493.1%   
Total wages/salary Rs m3,6491,801 202.6%   
Avg. sales/employee Rs Th10,184.410,748.9 94.7%   
Avg. wages/employee Rs Th984.12,395.2 41.1%   
Avg. net profit/employee Rs Th2,998.52,641.1 113.5%   
INCOME DATA
Net Sales Rs m37,7648,083 467.2%  
Other income Rs m848829 102.3%   
Total revenues Rs m38,6128,913 433.2%   
Gross profit Rs m14,138234 6,036.5%  
Depreciation Rs m1,18237 3,220.2%   
Interest Rs m232 1,288.9%   
Profit before tax Rs m13,7811,025 1,344.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m2,662752 354.0%   
Profit after tax Rs m11,1191,986 559.8%  
Gross profit margin %37.42.9 1,292.1%  
Effective tax rate %19.373.4 26.3%   
Net profit margin %29.424.6 119.8%  
BALANCE SHEET DATA
Current assets Rs m30,94712,678 244.1%   
Current liabilities Rs m5,1952,433 213.5%   
Net working cap to sales %68.2126.7 53.8%  
Current ratio x6.05.2 114.3%  
Inventory Days Days11733 357.1%  
Debtors Days Days8522 378.6%  
Net fixed assets Rs m17,02769 24,605.2%   
Share capital Rs m531160 332.2%   
"Free" reserves Rs m42,34111,460 369.5%   
Net worth Rs m42,87711,621 369.0%   
Long term debt Rs m50-   
Total assets Rs m49,68414,400 345.0%  
Interest coverage x595.0570.5 104.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.6 135.4%   
Return on assets %22.413.8 162.4%  
Return on equity %25.917.1 151.7%  
Return on capital %32.223.6 136.5%  
Exports to sales %85.30.7 11,448.3%   
Imports to sales %22.918.6 123.3%   
Exports (fob) Rs m32,19860 53,485.0%   
Imports (cif) Rs m8,6541,503 575.9%   
Fx inflow Rs m32,270186 17,321.8%   
Fx outflow Rs m8,7751,821 481.9%   
Net fx Rs m23,496-1,635 -1,437.5%   
CASH FLOW
From Operations Rs m10,3792,531 410.1%  
From Investments Rs m-4,135-8,270 50.0%  
From Financial Activity Rs m-6,241-386 1,618.2%  
Net Cashflow Rs m3-6,125 -0.1%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.8 2.0 590.0%  
FIIs % 19.0 1.6 1,187.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 21.5 80.0%  
Shareholders   31,796 41,647 76.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   STRIDES SHASUN LTD  ELDER PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 22, 2017 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - SHASUN PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS